Sanguine Biosciences gets $10 million financing via Catalio Capital

By Marisa Wong

Los Angeles, Oct. 31 – Sanguine Biosciences announced it secured $10 million of credit financing from Catalio Capital Management’s Structured Opportunities Fund, according to a press release.

The senior secured term loan provides Sanguine with an initial draw of $6 million at close, with an additional $4 million available at the company’s option.

Sanguine will use the funds to support its recently launched apheresis donation center, develop instrumental cell and gene therapy products derived from apheresis, including GMP-grade and CD34+ mobilized leukopaks and fund commercial growth.

The biospecimen procurement services company is based in Woburn, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.